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Inflammasomes are specialized signaling platforms critical 
for the regulation of innate immune and inflammatory 
responses. Various NLR family members (i.e., NLRP1, 
NLRP3, and IPAF) as well as the PYHIN family member 
AIM2 can form inflammasome complexes. These multi-
protein complexes activate inflammatory caspases (i.e., 
caspase-1) which in turn catalyze the maturation of select 
pro-inflammatory cytokines, including interleukin (IL)-1 
and IL-18. Activation of the NLRP3 inflammasome typically 
requires two initiating signals. Toll-like receptor (TLR) and 
NOD-like receptor (NLR) agonists activate the transcription 
of pro-inflammatory cytokine genes through an NF-B-
dependent priming signal. Following exposure to extracel-
lular ATP, stimulation of the P2X purinoreceptor-7 (P2X7R), 
which results in K
+ efflux, is required as a second signal 
for NLRP3 inflammasome formation. Alternative models 
for NLRP3 activation involve lysosomal destabilization and 
phagocytic NADPH oxidase and /or mitochondria-depen-
dent reactive oxygen species (ROS) production. In this 
review we examine regulatory mechanisms that activate 
the NLRP3 inflammasome pathway. Furthermore, we dis-
cuss the potential roles of NLRP3 in metabolic and 
cognitive diseases, including obesity, type 2 diabetes 
mellitus, Alzheimer’s disease, and major depressive 
disorder. Novel therapeutics involving inflammasome 
activation may result in possible clinical applications in the 
near future. 
1 
 
INTRODUCTION 
 
Inflammation involves a tightly regulated process, characterized 
by two complementary subsystems: the innate immune system 
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and the subsequent, highly adaptive immune system. The in-
nate immune system is activated by invasive pathogens that 
target pattern recognition receptors (PRRs), such as mem-
brane-bound Toll-like receptors (TLRs) and cytosolic NOD-like 
receptors (NLRs). While TLRs detect both extracellular and 
intracellular stimuli, NLRs respond to cytosolic agonists. The 
NLR family contains various proteins that act as scaffolds that 
can oligomerize into larger protein complexes, thereby inducing 
the formation of a molecular platform called the inflammasome. 
These multi-protein complexes contribute to the activation of 
inflammatory caspases (i.e., caspase-1) that result in the prote-
olytic processing and secretion of cytokines, including interleu-
kin (IL)-1 and IL-18 (Martinon et al., 2009). Therefore, inflam-
masomes, which include members of the NLR family (i.e., 
NLRP1, NLRP3, and IPAF) as well as the PYHIN family mem-
ber AIM2, represent critical mediators of cellular stress in the 
innate and adaptive immune systems (Fig. 1). This review will 
discuss the importance of inflammasome pathways, specifically, 
that of the most fully characterized NLRP3 inflammasome, in 
metabolic and cognitive diseases, including obesity, type 2 
diabetes mellitus, Alzheimer’s disease, and major depressive 
disorder (Fig. 2). 
 
STRUCTURAL ORGANIZATION 
 
The NLR family 
The NLR protein family consists of the NLRPs (NLRP1-14, or 
NALP1-14) and the ICE-protease-activating factor (IPAF) sub-
family. Most NLRs contain the nucleotide-binding and oligomer-
ization (NACHT) domain, which enables activation of the pro-
inflammatory cytokine signaling pathways via ATP-dependent 
oligomerization. The NACHT domain is usually surrounded by 
C-terminal leucine-rich repeats (LRRs) and an N-terminal 
caspase and recruitment domain (CARD) or pyrin domain 
(PYD) (Schroder and Tschopp, 2010). The PYD domain of 
NLRPs recruits the adaptor apoptosis-associated speck-like 
protein containing a caspase recruitment domain (ASC), which 
contains an N-terminal PYD and a C-terminal CARD. Further-
more, the CARD domain of ASC represents an essential com-
ponent for inflammasome formation via caspase-1 binding 
(Mariathasan et al., 2004; Martinon et al., 2002). 
The NLRP1, NLRP3, and IPAF inflammasomes harbor struc-
tural distinctions that enable caspase-1 recruiting. The NLRP1 
inflammasome contains a C-terminal CARD that recruits pro-
caspase-1 (Faustin et al., 2007) or pro-caspase-5 (Martinon et 
al., 2002). As a result, NLRP1 does not require recruitment of 
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Fig. 2. NLRP3 has been implicated in pro-pathogenic responses 
related to several human diseases, including neurocognitive disor-
ders and metabolic disorders, although the mechanisms remain 
incompletely clear. Neurons and astrocytes may represent targets 
of NLRP3-dependent inflammatory processes, leading to the pro-
motion of neurocognitive disorders. Adipocyte differentiation and 
growth have been linked to NLRP3-dependent processes in obesity. 
Hepatic insulin resistance and inflammation may also be mediated 
in part by NLRP3-dependent inflammation. 
 
ASC to interact directly with caspase-1. However, ASC has 
been shown to enhance NLRP1-mediated caspase-1 activation 
in vitro (Faustin et al., 2007). In contrast to most proteins of the 
NLR family, the NLRP3 protein lacks the typical CARD domain. 
The PYD domain of NLRP3 interacts with ASC, whose CARD 
domain recruits the CARD of pro-caspase-1 (Schroder and 
Tschopp, 2010). Finally, the IPAF protein lacks a PYD domain 
(Schroder and Tschopp, 2010), but contains a CARD domain 
that interacts directly with pro-caspase-1 without the need of 
ASC (Poyet et al., 2001). Therefore, IPAF may interact with a 
PYD-containing protein (i.e., NLRPs) for appropriate inflamma-
tory responses to invasive pathogens (Schroder and Tschopp, 
2010). 
 
AIM2 inflammasome 
The pyrin and HIN domain-containing protein (PYHIN) family 
member absent in melanoma 2 (AIM2 inflammasome) repre-
sents the first non-NLR family member identified that can form 
an inflammasome complex (Ludlow et al., 2005; Schroder and 
Tschopp 2010). While most inflammasomes in the NLR family 
depend on a central NACHT domain for oligomerization, AIM2 
uses multiple binding sites for cytosolic DNA via its C-terminal 
HIN200 domain. Similar to NLRP3, AIM2 contains a PYD do-
main that interacts with ASC via homotypic PYD-PYD interac-
tions, which allows the CARD domain within ASC to regulate 
nuclear factor kappa B (NF-B) and caspase-1 production 
(Hornung et al., 2009). As a result, AIM2-mediated caspase-1 
activation induces pro-inflammatory cytokine secretion (i.e., IL-
1, IL-18) (Schroder and Tschopp, 2010). 
 
NLRP3 INFLAMMASOME ACTIVATION  
AND REGULATION 
 
TLR-dependence 
TLRs are critical receptors that regulate inflammasome activity 
and pro-IL-1 production. TLR agonists, such as lipopolysaccha-
ride (LPS), induce pro-IL-1 secretion via the NF-B transcription 
factor and IL-1 promoter activation (Hiscott et al., 1993; 
Schroder and Tschopp, 2010). Prior to caspase-1-mediated pro-
Fig. 1. The NLRP3 inflammasome regulates the
caspase-1 dependent maturation and secretion of
pro-inflammatory cytokines. Activation of the
NLRP3 inflammasome typically requires a bimod-
al signaling pathway. A Toll-like receptor (TLR)-
dependent priming step activates the NF-B-
dependent transcription of NLRP3 and the pro-
forms of the pro-inflammatory cytokines (i.e., IL-1
and IL-18). A second signal involves the activation
of the P2X7R receptor by stimulation with exoge-
nous ATP, which triggers potassium ion (K
+) efflux.
Oligomerization of NLRP3 is followed by recruit-
ment of the adaptor molecule ASC and the pro-
form of caspase-1, leading to the activation
(cleavage) of caspase-1. Activated caspase-1 in
turn catalyzes the cleavage of IL-1 and IL-18.
The NLRP3 inflammsome may be activated by
agents that cause mitochondrial dysfunction,
leading to the generation of mitochondrial reactive
oxygen species (ROS). Furthermore, the NLRP3 inflammasome may be activated by particulates such as monosodium urate or silica, in a
mechanism that may involve disruption of the lysosomes. Inflammasomes in Disease 
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teolytic cleavage of IL-1, TLR agonists facilitate the NLRP3 
inflammasome pathway through an NF-B-dependent priming 
signal, which may represent a rate-limiting component of in-
flammasome complex formation (Bauernfeind et al., 2009; 
Guarda et al., 2011). Other studies have suggested the im-
portance of TLR4 in the inflammasome pathway. For example, 
CD14, a phagocyte-expressed PRR known to interact with 
TLR4, increased TLR4-mediated inflammatory response to 
LPS (Fujihara et al., 2003) and monosodium urate (MSU) 
(Scott et al., 2006). Furthermore, LPS failed to induce NLRP3 
or pro-IL-1 activation in cells lacking a functional TLR4 recep-
tor (Bauernfeind et al., 2009). Franchi et al. (2009) demonstrat-
ed that the presence of ATP was required for TLR4-dependent 
caspase-1 activation following exposure to LPS.  
 
ATP-dependence 
Extracellular ATP activates the P2X purinoreceptor 7 (P2X7R) 
via the pannexin-1 hemichannel, which was proposed to permit 
the bacterial ligand to enter the cytosol to induce caspase-1 
expression (Kanneganti et al., 2007). P2X7R-dependent pro-
caspase-1 activation and IL-1 secretion have been found to 
facilitate NF-B activation via a TNF-α-dependent pathway, 
thereby suggesting an important role of P2X7R in NLRP3 in-
flammasome complex formation (Solini et al., 2013; Wen et al., 
2011). ATP-mediated P2X7R stimulation has also been shown 
to induce a K
+ efflux, which indicates that reduced intracellular 
K
+ concentration triggers the NLRP3 inflammasome pathway 
(Pétrilli et al., 2007). Furthermore, suppressed NLRP3 activity 
has been reported to result from treatment with the ATP-
sensitive K
+ channel inhibitor, glibenclamide, and the chemical 
ROS scavenger, (2R,4R)-4-aminopyrrolidine-2, 4-dicarboxylate 
(APDC) (Allen, 2009; Nakahira, 2011). However, P2X7R-
deficient and wild type mice exhibit similar levels of adipocyte 
cell death in a diet-induced obesity model (Sun et al., 2012). 
Furthermore, a recent study has shown that pannexin-1 is not 
required for P2X7R function during activation of the NLRP3, 
IPAF, and AIM2 inflammasomes (Qu et al., 2011). As a result, 
activation of the inflammasome pathway may not strictly de-
pend on the presence of ATP in vivo. 
 
Alternative pathways and ROS-dependence 
Recent studies have proposed an alternative model for NLRP3 
inflammasome formation that involves lysosomal destabilization 
due to engulfment of crystalline or particulate agonists 
(Schroder and Tschopp, 2010). For example, macrophage cells 
treated with silica crystals or MSU displayed swollen lysosomes 
and dispersion of lysosomal contents in the cytosol (Hornung et 
al., 2008). The antibiotic nigericin can induce lysosomal rupture 
via cathepsin B, a cysteine protease found in the lysosome, 
and subsequent caspase-1 activation via K
+ efflux (Heid et al. 
2013; Hentze et al., 2003). Moreover, since pannexin-1 is re-
quired for nigericin-induced NLRP3 inflammasome formation 
(Pelegrin and Surprenant, 2006; 2007) and enables larger ly-
sosomal pores, pannexin-1 may induce lysosomal destabiliza-
tion (Hornung et al., 2008). Furthermore, the same study re-
ported that cells undergoing lysosomal rupture lose cathepsin B, 
thereby inducing caspase-1 activation, which suggests that the 
NLRP3 inflammasome recognizes lysosomal damage and 
subsequent lysosomal content in the cytoplasm following 
phagocytosis of NLRP3 agonists (Hornung et al., 2008). 
Environmental stimuli, such as asbestos and silica, can acti-
vate the NLRP3 inflammasome complex via phagocytic 
NADPH oxidase-induced reactive oxygen species (ROS) pro-
duction (Dostert et al., 2008). For example, NADPH oxidase 
inhibitors, diphenylene iodonium (DPI) and apocynin, and 
knockdown of the NADPH oxidase subunit p22
phox have been 
shown to reduce IL-1 production. Similar inhibitory effects on 
inflammasome activation have been reported for ROS inhibitors, 
N-acetyl-L-cysteine (NAC) and APDC, in response to asbestos, 
MSU, and ATP (Dostert et al., 2008). P2X7R has been shown to 
mediate NADPH oxidase-dependent oxidative stress both in 
vivo (Chatterjee et al., 2012) and in vitro (Korcok et al., 2004; 
Liu et al., 2011), thereby indicating a critical role for P2X7R in 
activation of the NLRP3 inflammasome via ROS signaling. 
Furthermore, recent studies suggest that treatment of mac-
rophages with the mitochondria-targeted antioxidant Mito-
TEMPO, a TEMPOL derivative that targets mitochondrial ROS 
(Trnka et al., 2009), reduced secretion of both IL-1 and IL-18. 
Mito-TEMPO inhibited subsequent caspase-1 activation and 
mitochondrial DNA (mtDNA) translocation to the cytosol in re-
sponse to LPS and ATP (Nakahira et al., 2011). However, Mito-
TEMPO did not inhibit IL-1 secretion following exposure to 
treatment with LPS and MSU, indicating that this pathway is 
independent of mitochondrial ROS (Nakahira et al., 2011). In 
conclusion, while ROS production represents a critical prereq-
uisite to the NLRP3 inflammasome pathway, the source of ROS 
may vary with experimental models. 
 
NLRP3 inflammasome in metabolic disorders 
Recently, the prevalence of metabolic disorders, such as obesi-
ty, type 2 diabetes mellitus (T2DM), and atherosclerosis has 
risen tremendously (Davis et al., 2011). The World Health Or-
ganization (WHO) estimates that over 2.8 million adults above 
the age of 20 die each year worldwide due to being overweight 
(BMI ≥ 25 kg/m
2) or suffering from obesity (BMI ≥ 30 kg/m
2). In 
2008, 10-14% of adults were clinically obese, in contrast to 5-
8% of men and women in 1980 (Finucane et al., 2011; WHO, 
2011). Furthermore, obesity increases the risk of diabetes, 
heart disease, stroke, hypertension, and depression (WHO, 
2002). In 2008, diabetes alone accounted for 1.3 million deaths 
(WHO, 2011). In recent years, several studies have illustrated 
the chronic pro-inflammatory processes involved in the onset of 
metabolic disorders, including obesity and diabetes (Davis et al., 
2011). 
Obesity can stem from a variety of factors, such as genetics, 
aging, and unhealthy lifestyle habits (Skeldon et al., 2014). 
Adipose tissue in obese individuals releases more free fatty 
acids, hormones (i.e., leptin), pro-inflammatory cytokines (i.e., 
TNF-, IL-1), signaling proteins, and transcription factors that 
lead to insulin resistance (Shoelson et al., 2006; Wellen and 
Hotamisligil, 2005). Insulin resistance associated with dysfunc-
tional insulin release from pancreatic islet -cells impairs blood 
glucose tolerance, which typifies the development of T2DM 
(Kahn et al., 2006). 
 
Obesity 
Inflammation is associated with metabolic disorders, such as 
obesity. Recent studies have shown that the NLRP3 inflam-
masome may contribute to obesity. For example, weight loss 
due to calorie restriction or exercise in obese individuals with 
T2DM not only reduced NLRP3 expression and inflammation in 
adipose tissue and liver, but also improved insulin sensitivity 
(Vandanmagsar et al., 2011). In addition, mice deficient in 
NLRP3, ASC, and caspase-1 did not exhibit obesity-induced 
insulin resistance, which suggests that the NLRP3 inflam-
masome may act as a cellular regulator of insulin sensitivity 
(Vandanmagsar et al., 2011). However, since loss of NLRP3 
function did not affect caspase-1 activation in the kidney of Inflammasomes in Disease 
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obese mice, inflammasomes may contribute to obesity via tis-
sue-specific mechanisms (Vandanmagsar et al., 2011). 
Two recent reports have implicated that caspase-1 may regu-
late lipid metabolism, thereby controlling the induction of obesity. 
Both studies showed that Casp1
-/- mice with lean phenotype 
exhibited reduced plasma triglyceride levels (Kotas et al., 2013; 
van Diepen et al., 2013). While van Diepen et al. (2013) illus-
trated a marked decrease in intestinal lipid absorption, Kotas et 
al. (2013) found enhanced triglyceride clearance from the circu-
lation without alterations in lipid production or intestinal. The 
lipid clearance in Casp1
-/- mice was also observed in NLRP3
-/- 
mice, irrespective of IL-1 and IL-18 signaling (Kotas et al., 
2013). Therefore, the NLRP3 inflammasome appears to affect 
lipid metabolism in obesity independently of IL-1 and IL-18 
signaling. However, negligible changes in triglyceride and cho-
lesterol levels were observed in obese Casp1
-/- or NLRP3
-/- mice 
(Stienestra et al., 2010; 2011; Vandanmagsar et al., 2011). Thus, 
the role of NLRP3 activation in lipid metabolism related to obe-
sity remains unclear. 
Release of the NLRP3 inflammasome following diet-induced 
obesity has been shown to induce adipocyte differentiation, 
which also enhanced IL-1 production and insulin resistance in 
adipose tissue (Stienstra et al., 2010) and increased adipocyte 
size (Stienstra et al., 2011). Elevated MSU levels have been 
linked to oxidative stress in adipocytes and obesity (Sautin et al., 
2007). Considering the recognition of MSU by the NLRP3 in-
flammasome, thereby inducing an inflammatory response, 
NLRP3 activation may contribute to insulin resistance in obesity 
(Hornung et al., 2008; Martinon et al., 2006). Furthermore, in-
hibited recognition of such stimuli due to NLRP3 dysfunction 
may prevent chronic obesity (Vandanmagsar et al., 2011). 
 
Type 2 diabetes mellitus (T2DM) 
Type 2 diabetes mellitus (T2DM) is an auto-inflammatory dis-
ease induced by metabolic stressors, such as elevated levels of 
glucose and free fatty acids (FFAs) (Donath and Shoelson, 
2011). Many studies have indicated a critical role of inflammato-
ry processes in cases related to T2DM. For example, pro-
inflammatory cytokines, TNF-, IL-1 and IFN, activate signal-
ing pathways that result in pancreatic -cell death and dysfunc-
tion (Eizirik et al., 2012; Feve et al., 2009; Mraz et al., 2011). As 
a result, elevated IL-1 levels and limited -cell function are two 
primary predictors for the development of T2DM through inhibi-
tion of insulin signaling (Wang et al., 2014a). Additionally, recent 
studies have shown that inhibition of IL-1 production reduced 
T2DM prevalence in animal models (Emanuela et al., 2012; 
Mandrup-Poulsen et al., 2010). Furthermore, NLRP3-
dependent IL-1 secretion during metabolic stress due to 
chronic hyperglycemia may contribute to the development of 
T2DM (Schroder et al., 2010). These findings suggest that IL-
1 production via NLRP3 inflammasome activation is involved 
in the pathogenesis of T2DM. 
The NLRP3 inflammasome has been shown to bind to thi-
oredoxin interacting protein (TXNIP), which facilitates ROS-
mediated NLRP3 activation via inhibition of thioredoxin (Skel-
don et al., 2014). A recent study has illustrated a potential role 
for TXNIP in innate immunity via formation of the NLRP3 in-
flammasome and release of IL-1 in diabetes and oxidative 
stress (Devi et al., 2012). Also, pancreatic -cell death and 
insulin resistance in T2DM have been associated with IL-1 
secretion mediated by the ROS-TXNIP axis, thereby enhancing 
NLRP3 activation (Zhou et al., 2010). This involvement of ROS-
TXNIP in T2DM is consistent with the requirement for ROS in 
the NLRP3 inflammasome pathway (Wang et al., 2014a). 
Therefore, the NLRP3 inflammasome may contribute to the 
pathogenesis of T2DM via the TXNIP protein (Wang et al., 
2014a). However, the mechanisms that induce ROS generation 
in response to metabolic stress, such as chronic hyperglycemia, 
remain incompletely understood. 
Targeting specific components of the inflammasome pathway 
may provide a plausible approach for treatment of T2DM. For 
example, glibenclamide, a drug widely used to treat T2DM, has 
been shown to inhibit formation of the glucose-induced TXNIP-
NLRP3 inflammasome complex (Zhou et al., 2010). Palmitate, 
a saturated fatty acid found in plasma, triggers the secretion of 
IL-1 and IL-18 from macrophages via an NLRP3-dependent 
pathway (Wen et al., 2011). In addition, islet amyloid polypep-
tide (IAPP), a protein that forms amyloid deposits in the pan-
creas during T2DM, enhanced IL-1 secretion and NLRP3 
activation in vitro (Masters et al., 2010). However, this same 
study reported that IL-1 release in response to IAPP depend-
ed on NLRP3, but not TXNIP (Masters et al., 2010). Therefore, 
TXNIP appears to represent an agonist-dependent protein 
within the NLRP3 inflammasome pathway. 
 
NLRP3 inflammasome in cognitive diseases 
Although neurocognitive diseases, such as Alzheimer’s disease, 
Parkinson’s disease, Huntington’s disease, and major depres-
sive disorder (MDD), are not often characterized as typical 
inflammatory diseases, recent research has indicated that acti-
vation of the innate immune system may contribute to their 
pathogenesis (Glass et al., 2010). PRRs, such as the TLR4 
receptor, are highly expressed on immune cells (i.e., microglia 
and astrocytes) that induce inflammatory processes via cyto-
kine secretion (Saijo et al., 2009). Considering that TLR4 poly-
morphisms have been linked to several human age-related 
diseases (i.e., Alzheimer’s disease, atherosclerosis, and T2DM), 
such receptors may influence neurodegenerative diseases via 
inflammatory responses (Balistreri et al., 2009). In addition to 
PRRs, purinergic receptors (i.e., P2X7R) are expressed on 
microglia and astrocytes. Furthermore, upregulation of this 
receptor has been reported in mouse models of Alzheimer’s 
disease (Parvathenani et al., 2003). Thus, PRRs and purinergic 
receptors on immune cells appear not only to serve as initial 
sensors of microbial pathogens, but they also likely induce 
inflammatory pathways associated with cognitive diseases, 
such as Alzheimer’s disease and MDD (Glass et al., 2010). 
 
Alzheimer’s disease 
Alzheimer’s disease is characterized by progressive dementia 
that stems from accumulation of amyloid-beta (A) plaques in 
the cerebrum, which leads to chronic inflammation and subse-
quent neuronal cell death (Leemans et al., 2011). During the 
1980s, patients suffering from Alzheimer’s disease exhibited 
elevated levels of microglia, the primary phagocyte in the cen-
tral nervous system (CNS) (Itagaki et al., 1989; McGeer et al., 
1987). Since then, amyloid plaques have been shown to acti-
vate microglia, thereby inducing the neuronal abnormalities 
associated with Alzheimer’s disease (Meyer-Luehmann et al., 
2008). However, it is still debated whether A accumulation is 
the result of chronic inflammation in amyloid-effected tissue or 
other disease-related processes (Leemans et al., 2011). 
Numerous studies have identified a critical role for IL-1 and 
the NLRP3 inflammasome in the pathogenesis of Alzheimer’s 
disease. For example, Halle et al. (2008) reported that A 
phagocytosis induced IL-1 secretion via NLRP3-dependent 
activation of caspase-1, thereby suggesting involvement of the 
NLRP3 inflammasome in Alzheimer’s disease. Exposing LPS-Inflammasomes in Disease 
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primed macrophages to fibrillar A activated caspase-1 and 
triggered IL-1 release; this response was dependent on 
NLRP3 and involved both endosomal rupture and cathepsin B 
release (Halle et al., 2008). Furthermore, inhibition of cathepsin 
B has been shown to provide therapeutic benefit in a mouse 
model of Alzheimer’s disease (Hook et al., 2008). Considering 
the role of cathepsin B in caspase-1 activation, this finding pro-
vides further evidence for the involvement of the NLRP3 in-
flammasome pathway in Alzheimer’s disease. 
A recent study reported upstream inflammatory processes in 
the context of Alzheimer’s disease in vivo (Heneka et al., 2013). 
NLRP
-/- or Casp1
-/- mice crossed into APP/PS1 transgenic mice 
with mutations associated with Alzheimer’s disease (Jankowsky 
et al., 2001) exhibited reduced symptoms associated with this 
cognitive disease, including chronic A secretion, neuronal 
inflammation, and cognitive impairment (Heneka et al., 2013). 
The same study demonstrated reduced release of caspase-1 
and IL-1 in the brain and enhanced A clearance, which sug-
gests that NLRP3 functions in the pathogenesis of Alzheimer’s 
disease (Heneka et al., 2013). More importantly, these findings 
indicate that innate immune responses, specifically those relat-
ed to inflammasome activation, contribute to neurocognitive 
disease onset and progression. 
 
Major depressive disorder (MDD) 
Major depressive disorder (MDD), also known as depression, is 
a severe neuropsychiatric illness that involves significant 
changes in mood, self-esteem, circadian rhythms, eating, and 
cognition (Iwata et al., 2013). While MDD affects at least 10% of 
the population in the United States (Kessler et al., 2003), its 
biosynthetic pathway remains unresolved. Previous studies 
suggest that environmental stimuli can lead to inflammatory 
processes (i.e., cytokine secretion and NLRP3 inflammasome 
activation), neurological changes, and MDD onset. For exam-
ple, inflammatory cytokines (i.e., IL-1, IL-6, and TNF-) have 
been shown to play an important role in major depression 
(Dowlati et al., 2010; Maes et al., 1993). Moreover, Iwata and 
colleagues have proposed that IL-1 secretion represents the 
initial step of the pro-inflammatory response to psychological 
stress (Iwata et al., 2013). In agreement with this proposal, IL-
1 release has been implicated to facilitate depressive behav-
iors (i.e., anhedonia) via the NF-B pathway following both 
acute (i.e., foot-shock or immobilization) and chronic unpredict-
able stress (Koo and Duman, 2008). 
Recent literature has examined a close relationship between 
depression and the NLRP3 inflammasome. For example, pa-
tients diagnosed with MDD exhibit increased levels of cytokines, 
IL-1 and IL-18, as well as the NLRP3 inflammasome in pe-
ripheral blood mononuclear cells (PBMCs) (Alcocer-Gomez 
and Cordero, 2013). Also, IL-1 and NLRP3 inflammasome 
mRNA expression levels showed a significant increase in 
mouse brain following LPS-induced depression, which indi-
cates that IL-1 and NLRP3 act as inflammatory mediators for 
psychological stress and depression (Zhang et al., 2013). In 
contrast to recent studies that suggest a critical role for mito-
chondrial rupture during NLRP3 activation (Latz et al., 2013; 
Nakahira et al., 2011), the inflammasome pathway in MDD 
patients does not depend on mitochondrial dysfunction (Alco-
cer-Gomez and Cordero, 2013). As a result, the mechanisms 
underlying the effect of psychological stress on inflammasome 
formation are still debated. 
Of clinical relevance, several recent studies indicate that an-
tidepressant medications regulate inflammasome activation. 
For example, amitriptyline, a common tricyclic antidepressant, 
has been shown to inhibit IL-1 and IL-18 production, as well 
as NLRP3 and caspase-1 gene expression in MDD patients 
(Alcocer-Gomez and Cordero, 2013). In addition, glyburide, an 
anti-diabetic drug that inhibits caspase-1 activation and IL-1 
secretion, may also serve as an effective inhibitor of NLRP3 
formation following stress-induced depression (Lamkanfi et al., 
2009). Furthermore, Warner-Schmidt and colleagues found an 
antagonistic relationship between antidepressant drugs and 
anti-inflammatory agents in patients with depression (Warner-
Schmidt et al., 2011). Of note, selective serotonin reuptake 
inhibitors (SSRIs), but not tricyclic antidepressants, increased 
TNF- and IFN levels in the frontal cortex, which was inhibited 
by anti-inflammatory agents (i.e., NSAIDs) (Warner-Schmidt et 
al., 2011). This finding suggests that SSRIs and tricyclic antide-
pressants depend on different mechanisms to interact with anti-
inflammatory drugs. Therefore, future clinical trials should con-
sider the different effects of anti-inflammatory drugs on the effi-
cacy of antidepressant agents in patients suffering from de-
pression (Warner-Schmidt et al., 2011). 
Depression-induced NLRP3 activation has been shown to 
correlate with many comorbid systemic illnesses (i.e., diabetes, 
cancer, and cardiovascular disease) (Iwata et al., 2013; Menu 
and Vince, 2011). Since cytokine secretion and inflammasome 
formation respond to stimuli other than invasive pathogens (i.e. 
psychological stressors), the inflammasome may transduce 
such psychological stimuli into an inflammatory response. In an 
evolutionary sense, the inflammasome may have adapted its 
pathway over time to include psychological stress due to the 
social interaction and non-pathogenic danger signals from the 
environment (Raison and Miller, 2013). Considering the preva-
lence and potential consequences of major depressive disorder, 
future research should continue to focus on the role of inflam-
masome activation in this disease. 
 
CONCLUSION 
 
Inflammasomes are multi-protein complexes involved in the 
immune system and inflammation. In this review, we have 
elaborated on the involvement of the NLRP3 inflammasome in 
various metabolic and cognitive diseases, including obesity, 
type 2 diabetes mellitus, Alzheimer’s disease, and major de-
pressive disorder. In addition, other neurodegenerative diseas-
es, such as Parkinson’s disease (Lu et al., 2014; Wang et al., 
2014b) and Huntington’s disease (Glinsky, 2008), have been 
associated with the NLRP3 inflammasome. While this review 
focused on NLRP3, other inflammasomes, such as those be-
longing to the NLR family and the AIM2 inflammasome, may 
provide a foundation for future research. Due to potential plei-
otropic effects of inflammasome formation and their associated 
cytokines in various disease models, further elucidation of their 
regulation and functional significance is warranted. Novel ther-
apeutic strategies for modulation of inflammasome activation 
should continue to be developed for possible clinical application 
in the near future.   
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